{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:54:56Z","timestamp":1767146096825,"version":"build-2238731810"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.cyto.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T20:46:27Z","timestamp":1391460387000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: A population-based study (CoLaus Study)"],"prefix":"10.1016","volume":"66","author":[{"given":"Julien","family":"Vaucher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Marques-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Waeber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2014.01.003_b0005","first-page":"5","article-title":"Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions","volume":"64","author":"Libby","year":"1991","journal-title":"Lab Invest"},{"key":"10.1016\/j.cyto.2014.01.003_b0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cyto.2014.01.003_b0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cyto.2014.01.003_b0020","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cyto.2014.01.003_b0025","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2014.01.003_b0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.27.3.813","article-title":"Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes","volume":"27","author":"Pickup","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2014.01.003_b0035","doi-asserted-by":"crossref","first-page":"e21002","DOI":"10.1371\/journal.pone.0021002","article-title":"Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus study)","volume":"6","author":"Marques-Vidal","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2014.01.003_b0040","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. vol. 324; 2002. p. 71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"10.1016\/j.cyto.2014.01.003_b0045","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2014.01.003_b0050","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/01.CIR.100.8.793","article-title":"Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin","volume":"100","author":"Ikonomidis","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2014.01.003_b0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00029330-200601010-00006","article-title":"Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome","volume":"119","author":"Chen","year":"2006","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cyto.2014.01.003_b0060","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1463-1326.2007.00794.x","article-title":"Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial","volume":"10","author":"Hovens","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cyto.2014.01.003_b0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1160\/TH09-03-0177","article-title":"Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients","volume":"103","author":"Muhlestein","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cyto.2014.01.003_b0070","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1211\/jpp.61.11.0010","article-title":"Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome","volume":"61","author":"Gao","year":"2009","journal-title":"J Pharm Pharmacol"},{"issue":"488\u201396","key":"10.1016\/j.cyto.2014.01.003_b0075","first-page":"W174","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial","volume":"152","author":"Glynn","year":"2010","journal-title":"Ann Int Med"},{"key":"10.1016\/j.cyto.2014.01.003_b0080","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1160\/TH06-06-0337","article-title":"No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease","volume":"96","author":"Solheim","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cyto.2014.01.003_b0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2261-8-6","article-title":"The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome","volume":"8","author":"Firmann","year":"2008","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cyto.2014.01.003_b0090","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-1759(00)00238-6","article-title":"Multiplexed particle-based flow cytometric assays","volume":"243","author":"Vignali","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cyto.2014.01.003_b0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jri.2005.03.005","article-title":"Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants","volume":"66","author":"Dupont","year":"2005","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.cyto.2014.01.003_b0100","doi-asserted-by":"crossref","unstructured":"Kellar KL, Mahmutovic AJ, Bandyopadhyay K. Multiplexed microsphere-based flow cytometric immunoassays. Curr Protoc Cytom; 2006 [Chapter 13: Unit13 1].","DOI":"10.1002\/0471142956.cy1301s35"},{"key":"10.1016\/j.cyto.2014.01.003_b0105","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","volume":"14 Suppl 2","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.cyto.2014.01.003_b0110","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cyto.2014.01.003_b0115","first-page":"230","article-title":"Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European society of cardiology","volume":"28","author":"Vahanian","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cyto.2014.01.003_b0120","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","volume":"32","author":"Tendera","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cyto.2014.01.003_b0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1018644212794","article-title":"Effect of short-term aspirin use on C-reactive protein","volume":"9","author":"Feng","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cyto.2014.01.003_b0130","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0735-1097(01)01289-X","article-title":"Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay","volume":"37","author":"Feldman","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cyto.2014.01.003_b0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10641963.2010.503302","article-title":"The effect of aspirin on C-reactive protein in hypertensive patients","volume":"33","author":"Kim","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.cyto.2014.01.003_b0140","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCRESAHA.110.223883","article-title":"Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins","volume":"107","author":"Spite","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.cyto.2014.01.003_b0145","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1073\/pnas.96.14.8247","article-title":"Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo","volume":"96","author":"Clish","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cyto.2014.01.003_b0150","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1084\/jem.189.12.1923","article-title":"Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis","volume":"189","author":"Hachicha","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.cyto.2014.01.003_b0155","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-kappa B by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.cyto.2014.01.003_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)01828-9","article-title":"Anti-inflammatory effects of aspirin and sodium salicylate","volume":"447","author":"Amann","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cyto.2014.01.003_b0165","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/embor.2009.243","article-title":"IKK\/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis","volume":"10","author":"Bollrath","year":"2009","journal-title":"EMBO Rep"},{"key":"10.1016\/j.cyto.2014.01.003_b0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/ar2338","article-title":"Activator protein 1 (Fos\/Jun) functions in inflammatory bone and skin disease","volume":"10","author":"Zenz","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cyto.2014.01.003_b0175","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.4049\/jimmunol.1100967","article-title":"Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1","volume":"187","author":"Smolinska","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2014.01.003_b0180","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/ALN.0b013e31816d83e4","article-title":"STOP questionnaire: a tool to screen patients for obstructive sleep apnea","volume":"108","author":"Chung","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cyto.2014.01.003_b0185","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","article-title":"Effects of low-dose aspirin on acute inflammatory responses in humans","volume":"183","author":"Morris","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2014.01.003_b0190","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1161\/01.CIR.96.9.3042","article-title":"Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo","volume":"96","author":"Bhagat","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2014.01.003_b0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2014.01.003_b0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/000331970105200204","article-title":"Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction","volume":"52","author":"Balbay","year":"2001","journal-title":"Angiology"},{"key":"10.1016\/j.cyto.2014.01.003_b0205","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0002-9149(03)00897-X","article-title":"Influence of aspirin on inflammatory markers in patients after acute myocardial infarction","volume":"92","author":"Solheim","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cyto.2014.01.003_b0210","unstructured":"Tolonen H, Koponen P, Aroma A, Conti S, Graff-Iversen S, Gr\u00f8tvedt L, Kanieff M, Mindell J, Natunen S, Primatesta P, Verschuren M, Viet L, Kuulasmaa K. for the Feasibility of a European Health Examination Survey (FEHES) Project. Review of Health Examination Surveys in Europe. 2008;Helsinki, Finland: National Public Health Institute (KTL). Report No.: B18\/2008; 2008."},{"key":"10.1016\/j.cyto.2014.01.003_b0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2007.097360","article-title":"Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction","volume":"54","author":"Packard","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.cyto.2014.01.003_b0220","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncpcardio0938","article-title":"Mechanisms of disease: toll-like receptors in cardiovascular disease","volume":"4","author":"Frantz","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"}],"updated-by":[{"DOI":"10.1016\/j.cyto.2014.06.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000}}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466614000076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466614000076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T04:34:13Z","timestamp":1565152453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466614000076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1043466614000076"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2014.01.003","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: A population-based study (CoLaus Study)","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2014.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}